Europe Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (U.K., Germany, France, Italy, Russia, Nordic, Benelux, Rest of Europe) Forecasts, 2026-2034

Last Updated: September 21, 2026 | Author: Debashree Bora | Format:

Europe Cardiac Resynchronization Therapy (crt) Market Size

The Europe Cardiac Resynchronization Therapy (CRT) Market size was valued at USD 1.45 billion in 2025 and is projected to grow from USD 1.52 billion in 2026 to reach USD 2.22 billion by 2034, growing at a CAGR of 4.86% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

The CRT-D segment had the biggest market share because of high demand, accounting for 58.3% of all products in 2021. The fastest growth rate is anticipated in the CRT-P segment due to numerous technological developments. The top competitors on the market include Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK, and MicroPort Scientific Corporation.

Europe Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report.

Product Insights

The European market is segmented by CRT-D and CRT-P.CRT-D dominated the market over the forecast period.

Europe Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

End-User Insights

The European market is segmented by Hospitals, Cardiac Centre. Hospitals dominated the market over the forecast period.

Europe Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The Europe market is segmented by country into the U.K, Germany, France, Italy, and Spain. Germany dominates the country market and is expected to grow at a CAGR of 6.4% during the forecast period.

In the upcoming years, a significant increase in demand for cardiac resynchronization therapy is anticipated in Europe. The existence of significant market participants, the high prevalence of heart failure, and the advanced healthcare system explain this. For instance, the European Society of Cardiology questioned 11,088 patients between 2015 and 2017, accounting for 11% of the anticipated total number of implantations in the 42 participating countries in Europe. The results were released in December 2019. Clinical practice varied significantly by area, according to the research. A permanent ICD or pacemaker update accounted for about 28% of surgeries. 30% of CRT implants were pacemakers, and 70% were defibrillators. The UK, Germany, France, Italy, Spain, Hungary, the Czech Republic, Poland, and Slovakia had the most patients recruited for implantation.

List of Key and Emerging Players in Europe Cardiac Resynchronization Therapy (CRT) Market

Abbott

Boston Scientific Corporation

Medtronic

Biotronik SE & Co. Kg

Microport Scientific Corporation

LivaNova PLC

Medico S.R.L.

Key Industry Developments

June 2026

Abbott expanded its cardiac rhythm management portfolio across Europe with enhanced remote monitoring capabilities for cardiac resynchronization therapy (CRT) devices, improving patient follow-up and clinical decision-making.

April 2026

Medtronic strengthened its European electrophysiology and cardiac rhythm management portfolio by expanding AI-enabled programming and remote management capabilities for CRT systems.

February 2026

BIOTRONIK expanded the availability of its next-generation CRT devices across Europe, featuring enhanced battery longevity and advanced heart failure management algorithms.

October 2025

Boston Scientific expanded physician training and clinical education programs across Europe to support the adoption of advanced cardiac resynchronization therapy systems for heart failure patients.

July 2025

MicroPort CRM strengthened its European cardiac rhythm management portfolio by expanding commercialization of advanced CRT devices with improved remote monitoring and device optimization features.

Report Scope

Segmentation

By Product 2

CRT-Defibrillator
CRT-Pacemaker

By End User 4

Hospitals
Cardiac Centers
Ambulatory Surgical Centers
Other End Users

Competitive Coverage Abbott · Boston Scientific Corporation · Medtronic · Biotronik SE & Co. Kg · Microport Scientific Corporation

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The Europe cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 4.86% during the forecast period (2026-2034).

Key verticals adopting the Europe cardiac resynchronization therapy market include: Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE & Co. Kg, Microport Scientific Corporation, LivaNova PLC, Medico S.R.L.

Rising sedentary lifestyle is the key driver for the growth of the Europe cardiac resynchronization therapy market.

Growing aging population is one of the upcoming key trends in the Europe cardiac resynchronization therapy market.

About the Author

Debashree Bora

Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.